Phase 4 Type 2 Diabetes Trial, Recruiting NCT06989723 Sponsor: Seoul National University Bundang Hospital Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 4 Type 2 Diabetes Trial, Recruiting

NCT06989723
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 20 years old or older
  • You have type 2 diabetes that is not fully controlled, with a blood sugar measure (HbA1c) between 7% and 10%, and you are currently taking metformin alone, metformin with a sulfonylurea, metformin with a DPP-4 inhibitor, or a three-drug combination including metformin (note: if on three medications, the sulfonylurea would need to be stopped when joining the trial)
  • A liver scan done within the last 3 months has shown that you have fat buildup in your liver at a certain level or above (confirm with trial site)
  • You have at least one of the following: a large waist size (90 cm or more for men, 85 cm or more for women); high blood pressure or you take blood pressure medication; high triglycerides (fats in the blood) or you take cholesterol-lowering medication; low "good" (HDL) cholesterol; a blood test showing insulin resistance; or a blood test showing raised inflammation levels (confirm with trial site for exact values)
  • Your diabetes or metabolic medications have not changed in the past 3 months (unless your doctor confirms the change would not affect the study)

Who may not be able to join:

  • You use insulin or have type 1 diabetes
  • You have taken any of the following medications in the past 3 months: GLP-1 receptor agonist injections or pills (such as semaglutide or liraglutide), SGLT2 inhibitors (such as empagliflozin), rosiglitazone, vitamin E, or ursodeoxycholic acid
  • Your liver fat is caused by something other than metabolic issues, such as hepatitis B, hepatitis C, or alcohol-related liver disease
  • You take certain medications known to cause fat buildup in the liver, including valproic acid, estrogen, tamoxifen, amiodarone, or chloroquine
  • You have severe liver problems, shown by significantly abnormal liver blood tests, low protein levels in the blood, low platelet counts, or advanced liver disease (confirm with trial site for exact values)
  • You have severe kidney problems, including very low kidney function, end-stage kidney disease, or you are on dialysis
  • You have liver cancer, any active cancer, or cancer that has spread to other parts of the body
  • You have a history of bladder cancer or currently have bladder cancer
  • You have a history of heart failure or currently have heart failure
  • You have a terminal (end-of-life) illness
  • You have a history of gallstones, long-term pancreatitis, or a recent episode of acute pancreatitis
  • Your body weight is very low, with a BMI under 18.5 (confirm with trial site)
  • You are pregnant or planning to become pregnant
  • You have a known allergy or sensitivity to any ingredients in the study medications
  • You have a history of diabetic ketoacidosis (a serious diabetes complication involving very high blood sugar and acid buildup)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +82-31-787-7035

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Seoul National University Bundang Hospital
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Proportion of Participants Achieving HbA1c Treatment Targets; Change in Fibroscan Controlled Attenuation Parameter (CAP) Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov